Olivia Vizier

Immuneering uses bioinformatics to develop new medicines while also helping large pharmaceutical companies improve their treatments.

We at NeuBase have felt that there are fundamental deficiencies in the current approach to drug development. The traditional drug screening approach, which involves scouring libraries of chemicals and just seeing what works, is slow, costly, and ultimately translates to higher drug prices. We believe that there will be a revolution in the pharmaceutical industry

A couple months after raising CHF 2.5 million ($2.76 million) in initial seed funding, one-year-old Araris Biotech is topping off the round with another CHF 12.7 million ($14 million).

Rezolute, a small company based in Redwood City, California, and working in the rare pediatric disease space, is developing a new therapeutic option specifically for patients with congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder. For Rezolute, connecting and partnering with advocacy groups and physicians is paramount in clinical trial execution.

Amolyt Pharma, formerly Alizé Pharma 3, had announced earlier this year its plans to start a clinical trial of AZP-3601 by the end of 2020.

Fountain Therapeutics’ unique AI discovery platform prompted an invitation from Eli Lilly & Company to move Fountain headquarters to Lilly Gateway Labs. Company CEO Dr. John Dimos is making the most of it. 

Scynexis announced today that it has submitted a new drug application to the FDA for oral ibrexafungerp for the treatment of vulvovaginal candidiasis, the second most common cause of vaginitis.

Cidara Therapeutics has adopted key immuno-oncology principles and applied them to infectious disease, enabling the creation of a novel antiviral strategy – antiviral conjugates (AVCs). AVCs are long-acting, bispecific drugs that directly inhibit viral proliferation, whilst simultaneously

An oral coronavirus vaccine candidate has entered the clinical trial phase, bringing with it a possible option for those wary of needles. Vaxart Inc. announced on Tuesday that the first subject had received a dose of the VXA-CoV2-1 oral tablet in a Phase 1 clinical trial.

Technology Networks recently spoke with Brad Margus, CEO at Cerevance, to find out how the company is addressing key drug development challenges. In this industry insight, Margus tells us more about the company’s drug development pipeline and their lead candidate CVN424, which is currently being developed to treat Parkinson’s disease. He also explains how Cerevance’s Nuclear

Some of this work has already arrived, such as Helix’s COVID-19 test, which detects the coronavirus in thousands of samples collected at San Diego County test sites. Other efforts are several months away, including CalciMedica’s anti-inflammatory drug meant to help keep COVID-19 patients off ventilators; the biotech believes the treatment could be approved by May

Celyad Oncology is a clinical-stage biotechnology company centered on the development of chimeric antigen receptor (CAR) T-cell therapies for the treatment of cancer. This approach involves engineering patient or donor T cells to display a CAR that targets the immune cells to cancer cells via antigen–receptor binding.

Arrowhead Pharmaceuticals Inc. announced 24-week liver biopsy results in patients from an open-label phase 2 clinical study of ARO-AAT, a second-generation investigational RNA interference therapeutic intended for treatment of a liver disease associated with alpha-1 antitrypsin deficiency.

Craig Fraser, CEO and President, Windtree Therapeutics talks about acute heart failure, the number one reason for hospitalization in people over 65 and the fact that there has been little innovation in trying to improve cardiac function. Developing a novel dual action drug called istaroxime, Windtree is addressing both parts of the cycles of the

Valneva SE, a vaccine specialist created by a merger in 2013, is the only drugmaker in the U.S. and Europe developing an inactivated shot against the SARS-CoV-2 virus. The approach uses a sample of the coronavirus that has been killed to stimulate an immune response without causing the disease. The approach has been used for

Sudarshan Hebbar, CMO of CalciMedica, reveals how the FDA, ethics committees, and safety consortia have responded to helping to advance the application of novel therapeutics towards COVID.

COVID-19 resembles an endothelial disease and treating it with anti-inflammatory agents, similarly to other endothelial diseases, may be appropriate, according to a viewpoint published in the European Heart Journal.

On this week’s Tech Nation, Moira speaks with a company that paused its work on Hepatitis B to focus on treatments for COVID. Dr. Lawrence Blatt, the CEO of Aligos Therapeutics joins Moira to talk about their idea for treating COVID. Then, Tech Nation Health Chief Correspondent, Dr. Daniel Kraft tells us that all COVID

Named after the average length of the GI tract, 9 Meters’ larazotide is the first coeliac drug to enter Phase III trials. If things go to plan, larazotide could be approved by 2023, thereby overcoming the unmet needs that remain in this condition despite adherence to a gluten-free diet.

SOTIO’s genetically-engineered SO-C101 is showing promise as a monotherapy and combined with immunotherapies in pre-clinical tests and also recently in a phase I study. CBO Jens Hennecke, Ph.D. shared an update on the company’s Phase 1 Progress.

California-based INmune decided to leverage its TNF platform and launch a Phase II trial of its selective inhibitor of soluble TNF (sTNF), Quellor, in hospitalised Covid-19 patients. Quellor differs from the existing TNF inhibitors on the market, which are prescribed for inflammatory conditions ranging from rheumatoid arthritis, inflammatory bowel disease and psoriasis, because it only

In this article, Drug Target Review’s Hannah Balfour discusses with Chief Medical Officer of SOTIO, Richard Sachse, why interleukin 15 (IL-15) signalling has become a top target for cancer immunotherapies and how they designed their drug (SO-C101) to overcome some of the limitations of previous IL-15 and IL-2 targeted therapies.